Molecular Partners (MOLN) News Today $5.08 -0.14 (-2.68%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in JanuaryDecember 17, 2024 | globenewswire.comMolecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024December 8, 2024 | globenewswire.comMolecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024November 7, 2024 | globenewswire.comMolecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and ExpositionNovember 6, 2024 | markets.businessinsider.comMolecular Partners’ Promising Pipeline and Financial Stability Justify Buy RatingNovember 5, 2024 | markets.businessinsider.comMolecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-goingOctober 31, 2024 | globenewswire.comMolecular Partners Announces Pricing of $20 Million Underwritten OfferingOctober 25, 2024 | globenewswire.comMolecular Partners, Orano Med announce presentation of MP0712 dataOctober 22, 2024 | markets.businessinsider.comMolecular Partners stock climbs 6% on expanded radiopharmaceuticals dealOctober 22, 2024 | msn.comMolecular Partners Expands Agreement With Orano Med for Cancer TreatmentOctober 22, 2024 | marketwatch.comMolecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin TherapeuticsOctober 22, 2024 | finance.yahoo.comMolecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin TherapeuticsOctober 22, 2024 | globenewswire.comMolecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024October 22, 2024 | globenewswire.comMolecular Partners (NASDAQ:MOLN) Stock, Short Interest ReportOctober 22, 2024 | benzinga.comEquities Analysts Issue Forecasts for Molecular Partners AG's Q3 2024 Earnings (NASDAQ:MOLN)Molecular Partners AG (NASDAQ:MOLN - Free Report) - Stock analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for Molecular Partners in a report issued on Monday, October 7th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of ($0.63) forOctober 9, 2024 | marketbeat.comMolecular Partners (NASDAQ:MOLN) Upgraded to Strong-Buy by Leerink PartnrsLeerink Partnrs raised Molecular Partners to a "strong-buy" rating in a research note on Monday.October 8, 2024 | marketbeat.comMolecular Partners Announces upcoming poster presentations at the 2024 SITC Annual MeetingOctober 4, 2024 | globenewswire.comMolecular Partners (NASDAQ:MOLN) Stock Price Down 1.9%Molecular Partners (NASDAQ:MOLN) Stock Price Down 1.9%October 3, 2024 | marketbeat.comMolecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024September 27, 2024 | globenewswire.comIs Molecular Partners (VTX:MOLN) In A Good Position To Deliver On Growth Plans?September 25, 2024 | finance.yahoo.comImmunoPrecise Antibodies Ltd. (TQB.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comGenfit S.A. (XUP.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comMolecular Partners (NASDAQ:MOLN) Stock Price Down 0.3%Molecular Partners (NASDAQ:MOLN) Trading Down 0.3%September 11, 2024 | marketbeat.comMolecular Partners AG: Hold Rating with Adjusted Price Target Amidst Development Delays and Financial UncertaintiesAugust 29, 2024 | markets.businessinsider.comMolecular Partners Reports H1 2024 Corporate Highlights and FinancialsAugust 26, 2024 | globenewswire.comInvestors in Molecular Partners (VTX:MOLN) have unfortunately lost 69% over the last three yearsAugust 20, 2024 | finance.yahoo.comQuantum pumping in molecular junctions: Theoretical model could lead to switches and amplifiersAugust 16, 2024 | msn.comNew Framework for Capturing Wobbly Molecular MotionAugust 14, 2024 | msn.comShort Interest in Molecular Partners AG (NASDAQ:MOLN) Drops By 23.8%Molecular Partners AG (NASDAQ:MOLN - Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 65,800 shares, a decline of 23.8% from the June 30th total of 86,300 shares. Based on an average daily trading volume, of 26,900 shares, the short-interest ratio is currently 2.4 days.July 27, 2024 | marketbeat.comShort Interest in Molecular Partners AG (NASDAQ:MOLN) Drops By 25.1%Molecular Partners AG (NASDAQ:MOLN - Get Free Report) saw a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 86,300 shares, a decrease of 25.1% from the June 15th total of 115,200 shares. Based on an average trading volume of 26,600 shares, the days-to-cover ratio is presently 3.2 days.July 13, 2024 | marketbeat.comMolecular Partners (NASDAQ:MOLN) Shares Down 5.4% Molecular Partners (NASDAQ:MOLN) Trading Down 5.4%July 4, 2024 | marketbeat.comMolecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitJune 17, 2024 | globenewswire.comMolecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024June 14, 2024 | globenewswire.comMolecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024June 11, 2024 | globenewswire.comMolecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024June 1, 2024 | globenewswire.comInterim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 ProgramMay 16, 2024 | globenewswire.comTrading was temporarily halted for "MOLN" at 09:05 AM with a stated reason of "LULD pause."May 9, 2024 | marketbeat.comMOLN Molecular Partners AGMay 1, 2024 | seekingalpha.comMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of ActionApril 29, 2024 | finance.yahoo.comMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of ActionApril 29, 2024 | globenewswire.comLife Science Cares Launches in SwitzerlandApril 19, 2024 | globenewswire.comWe Think Molecular Partners (VTX:MOLN) Needs To Drive Business Growth CarefullyApril 18, 2024 | finance.yahoo.comMolecular Partners Announces All Board Proposals Approved at the Annual General MeetingApril 17, 2024 | globenewswire.comTrading was temporarily halted for "MOLN" at 03:04 PM with a stated reason of "LULD pause."April 12, 2024 | marketbeat.comTrading was temporarily halted for "MOLN" at 02:04 PM with a stated reason of "LULD pause."April 12, 2024 | marketbeat.comBeyond Benign, MilliporeSigma partner on green chemistryApril 4, 2024 | bizjournals.comTrading was temporarily halted for "MOLN" at 09:04 AM with a stated reason of "LULD pause."April 3, 2024 | marketbeat.comMolecular Partners Publishes Invitation to Annual General Meeting 2024March 26, 2024 | globenewswire.comLeerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)March 21, 2024 | markets.businessinsider.comMolecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023March 14, 2024 | globenewswire.com Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address This Crypto Is Set to Explode in December (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW MOLN Media Mentions By Week MOLN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MOLN News Sentiment▼0.000.60▲Average Medical News Sentiment MOLN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MOLN Articles This Week▼11▲MOLN Articles Average Week Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies uniQure News Today 89bio News Today Pliant Therapeutics News Today Relay Therapeutics News Today Keros Therapeutics News Today Anavex Life Sciences News Today Immunome News Today Kura Oncology News Today Tyra Biosciences News Today Erasca News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MOLN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
